kent pharma uk limited
kent pharma uk limited Company Information
Company Number
11576098
Next Accounts
Dec 2025
Shareholders
ds spring bidco limited
Group Structure
View All
Industry
Wholesale of pharmaceutical goods
Registered Address
2nd floor, connect 38, 1 dover place, ashford, kent, TN23 1FB
Website
www.kentpharm.co.ukkent pharma uk limited Estimated Valuation
Pomanda estimates the enterprise value of KENT PHARMA UK LIMITED at £106.7m based on a Turnover of £85.9m and 1.24x industry multiple (adjusted for size and gross margin).
kent pharma uk limited Estimated Valuation
Pomanda estimates the enterprise value of KENT PHARMA UK LIMITED at £132.7m based on an EBITDA of £10.7m and a 12.37x industry multiple (adjusted for size and gross margin).
kent pharma uk limited Estimated Valuation
Pomanda estimates the enterprise value of KENT PHARMA UK LIMITED at £16.6m based on Net Assets of £8.7m and 1.91x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Kent Pharma Uk Limited Overview
Kent Pharma Uk Limited is a live company located in ashford, TN23 1FB with a Companies House number of 11576098. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in September 2018, it's largest shareholder is ds spring bidco limited with a 100% stake. Kent Pharma Uk Limited is a young, large sized company, Pomanda has estimated its turnover at £85.9m with high growth in recent years.
Upgrade for unlimited company reports & a free credit check
Kent Pharma Uk Limited Health Check
Pomanda's financial health check has awarded Kent Pharma Uk Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 8 measures and has 3 areas for improvement. Company Health Check FAQs
8 Strong
1 Regular
3 Weak
Size
annual sales of £85.9m, make it larger than the average company (£25.6m)
£85.9m - Kent Pharma Uk Limited
£25.6m - Industry AVG
Growth
3 year (CAGR) sales growth of 21%, show it is growing at a faster rate (5.5%)
21% - Kent Pharma Uk Limited
5.5% - Industry AVG
Production
with a gross margin of 37.5%, this company has a lower cost of product (26.4%)
37.5% - Kent Pharma Uk Limited
26.4% - Industry AVG
Profitability
an operating margin of 11.4% make it more profitable than the average company (3.9%)
11.4% - Kent Pharma Uk Limited
3.9% - Industry AVG
Employees
with 74 employees, this is above the industry average (37)
74 - Kent Pharma Uk Limited
37 - Industry AVG
Pay Structure
on an average salary of £84.7k, the company has an equivalent pay structure (£75.7k)
£84.7k - Kent Pharma Uk Limited
£75.7k - Industry AVG
Efficiency
resulting in sales per employee of £1.2m, this is more efficient (£697.3k)
£1.2m - Kent Pharma Uk Limited
£697.3k - Industry AVG
Debtor Days
it gets paid by customers after 105 days, this is later than average (59 days)
105 days - Kent Pharma Uk Limited
59 days - Industry AVG
Creditor Days
its suppliers are paid after 79 days, this is slower than average (31 days)
79 days - Kent Pharma Uk Limited
31 days - Industry AVG
Stock Days
it holds stock equivalent to 140 days, this is more than average (62 days)
140 days - Kent Pharma Uk Limited
62 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 23 weeks, this is more cash available to meet short term requirements (11 weeks)
23 weeks - Kent Pharma Uk Limited
11 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 87.8%, this is a higher level of debt than the average (53.1%)
87.8% - Kent Pharma Uk Limited
53.1% - Industry AVG
KENT PHARMA UK LIMITED financials
Kent Pharma Uk Limited's latest turnover from March 2024 is £85.9 million and the company has net assets of £8.7 million. According to their latest financial statements, Kent Pharma Uk Limited has 74 employees and maintains cash reserves of £16 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | |
|---|---|---|---|---|---|---|
| Turnover | 85,857,000 | 76,194,000 | 53,729,000 | 48,799,000 | 43,847,000 | |
| Other Income Or Grants | ||||||
| Cost Of Sales | 53,653,000 | 52,153,000 | 42,605,000 | 34,541,000 | 30,970,000 | |
| Gross Profit | 32,204,000 | 24,041,000 | 11,124,000 | 14,258,000 | 12,877,000 | |
| Admin Expenses | 22,412,000 | 15,402,000 | 15,006,000 | 10,980,000 | 11,278,000 | |
| Operating Profit | 9,792,000 | 8,639,000 | -3,882,000 | 3,278,000 | 1,599,000 | |
| Interest Payable | 2,338,000 | 2,337,000 | 2,307,000 | 2,305,000 | 1,407,000 | |
| Interest Receivable | ||||||
| Pre-Tax Profit | 7,454,000 | 6,302,000 | -6,189,000 | 973,000 | 192,000 | |
| Tax | -1,812,000 | -1,279,000 | 921,000 | -249,000 | -114,000 | |
| Profit After Tax | 5,642,000 | 5,023,000 | -5,268,000 | 724,000 | 78,000 | |
| Dividends Paid | ||||||
| Retained Profit | 5,642,000 | 5,023,000 | -5,268,000 | 724,000 | 78,000 | |
| Employee Costs | 6,269,000 | 5,149,000 | 4,099,000 | 3,312,000 | 1,549,000 | |
| Number Of Employees | 74 | 72 | 68 | 62 | 41 | |
| EBITDA* | 10,727,000 | 10,741,000 | -2,558,000 | 3,344,000 | 1,655,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | |
|---|---|---|---|---|---|---|
| Tangible Assets | 86,000 | 145,000 | 952,000 | 781,000 | 122,000 | |
| Intangible Assets | 7,841,000 | 9,521,000 | 10,332,000 | 16,476,000 | 17,527,000 | |
| Investments & Other | 1,858,000 | 1,858,000 | 1,157,000 | |||
| Debtors (Due After 1 year) | ||||||
| Total Fixed Assets | 9,785,000 | 11,524,000 | 12,441,000 | 17,257,000 | 17,649,000 | |
| Stock & work in progress | 20,633,000 | 19,113,000 | 14,932,000 | 15,359,000 | 10,523,000 | |
| Trade Debtors | 24,808,000 | 14,391,000 | 11,244,000 | 8,656,000 | 10,128,000 | |
| Group Debtors | 10,085,000 | 5,426,000 | 653,000 | |||
| Misc Debtors | 2,263,000 | 1,417,000 | 1,638,000 | 3,292,000 | ||
| Cash | 16,015,000 | 9,930,000 | 2,940,000 | 8,625,000 | 1,656,000 | |
| misc current assets | ||||||
| total current assets | 61,456,000 | 55,782,000 | 35,959,000 | 34,931,000 | 25,599,000 | |
| total assets | 71,241,000 | 67,306,000 | 48,400,000 | 52,188,000 | 43,248,000 | |
| Bank overdraft | ||||||
| Bank loan | ||||||
| Trade Creditors | 11,647,000 | 11,962,000 | 11,067,000 | 8,443,000 | 6,539,000 | |
| Group/Directors Accounts | 12,915,000 | 9,741,000 | 9,847,000 | 9,938,000 | 3,591,000 | |
| other short term finances | ||||||
| hp & lease commitments | ||||||
| other current liabilities | 10,330,000 | 14,896,000 | 5,202,000 | 6,255,000 | 6,290,000 | |
| total current liabilities | 34,892,000 | 36,599,000 | 26,116,000 | 24,636,000 | 16,420,000 | |
| loans | 20,650,000 | 20,650,000 | 24,250,000 | 24,250,000 | 24,250,000 | |
| hp & lease commitments | ||||||
| Accruals and Deferred Income | ||||||
| other liabilities | 7,000,000 | 7,000,000 | ||||
| provisions | ||||||
| total long term liabilities | 27,650,000 | 27,650,000 | 24,250,000 | 24,250,000 | 24,250,000 | |
| total liabilities | 62,542,000 | 64,249,000 | 50,366,000 | 48,886,000 | 40,670,000 | |
| net assets | 8,699,000 | 3,057,000 | -1,966,000 | 3,302,000 | 2,578,000 | |
| total shareholders funds | 8,699,000 | 3,057,000 | -1,966,000 | 3,302,000 | 2,578,000 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Operating Profit | 9,792,000 | 8,639,000 | -3,882,000 | 3,278,000 | 1,599,000 | |
| Depreciation | 101,000 | 516,000 | 115,000 | 2,000 | 3,000 | |
| Amortisation | 834,000 | 1,586,000 | 1,209,000 | 64,000 | 53,000 | |
| Tax | -1,812,000 | -1,279,000 | 921,000 | -249,000 | -114,000 | |
| Stock | 1,520,000 | 4,181,000 | -427,000 | 4,836,000 | 10,523,000 | |
| Debtors | -1,931,000 | 8,652,000 | 7,140,000 | -2,473,000 | 13,420,000 | |
| Creditors | -315,000 | 895,000 | 2,624,000 | 1,904,000 | 6,539,000 | |
| Accruals and Deferred Income | -4,566,000 | 9,694,000 | -1,053,000 | -35,000 | 6,290,000 | |
| Deferred Taxes & Provisions | ||||||
| Cash flow from operations | 4,445,000 | 7,218,000 | -6,779,000 | 2,601,000 | -9,573,000 | |
| Investing Activities | ||||||
| capital expenditure | ||||||
| Change in Investments | 701,000 | 1,157,000 | ||||
| cash flow from investments | ||||||
| Financing Activities | ||||||
| Bank loans | ||||||
| Group/Directors Accounts | 3,174,000 | -106,000 | -91,000 | 6,347,000 | 3,591,000 | |
| Other Short Term Loans | ||||||
| Long term loans | -3,600,000 | 24,250,000 | ||||
| Hire Purchase and Lease Commitments | ||||||
| other long term liabilities | 7,000,000 | |||||
| share issue | ||||||
| interest | -2,338,000 | -2,337,000 | -2,307,000 | -2,305,000 | -1,407,000 | |
| cash flow from financing | 836,000 | 957,000 | -2,398,000 | 4,042,000 | 28,934,000 | |
| cash and cash equivalents | ||||||
| cash | 6,085,000 | 6,990,000 | -5,685,000 | 6,969,000 | 1,656,000 | |
| overdraft | ||||||
| change in cash | 6,085,000 | 6,990,000 | -5,685,000 | 6,969,000 | 1,656,000 |
kent pharma uk limited Credit Report and Business Information
Kent Pharma Uk Limited Competitor Analysis
Perform a competitor analysis for kent pharma uk limited by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other large companies, companies in TN23 area or any other competitors across 12 key performance metrics.
kent pharma uk limited Ownership
KENT PHARMA UK LIMITED group structure
Kent Pharma Uk Limited has 3 subsidiary companies.
Ultimate parent company
2 parents
KENT PHARMA UK LIMITED
11576098
3 subsidiaries
kent pharma uk limited directors
Kent Pharma Uk Limited currently has 4 directors. The longest serving directors include Mr David Wright (Sep 2019) and Mr David Wright (Sep 2019).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr David Wright | England | 60 years | Sep 2019 | - | Director |
| Mr David Wright | England | 60 years | Sep 2019 | - | Director |
| Mr Kevin James | England | 70 years | Mar 2022 | - | Director |
| Mr Terry Petersen | England | 51 years | Jul 2024 | - | Director |
P&L
March 2024turnover
85.9m
+13%
operating profit
9.8m
+13%
gross margin
37.6%
+18.88%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
8.7m
+1.85%
total assets
71.2m
+0.06%
cash
16m
+0.61%
net assets
Total assets minus all liabilities
Similar Companies
kent pharma uk limited company details
company number
11576098
Type
Private limited with Share Capital
industry
46460 - Wholesale of pharmaceutical goods
incorporation date
September 2018
age
7
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
March 2024
previous names
N/A
accountant
-
auditor
KPMG
address
2nd floor, connect 38, 1 dover place, ashford, kent, TN23 1FB
Bank
NATIONAL WESTMINSTER BANK PLC
Legal Advisor
DLA PIPER UK LLP
kent pharma uk limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 6 charges/mortgages relating to kent pharma uk limited. Currently there are 3 open charges and 3 have been satisfied in the past.
kent pharma uk limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for KENT PHARMA UK LIMITED. This can take several minutes, an email will notify you when this has completed.
kent pharma uk limited Companies House Filings - See Documents
| date | description | view/download |
|---|
